Tempus AI, Inc, aims to revolutionize precision medicine with AI technology and healthcare data. The promise looks good, as the revenue base is substantial, but unfortunately the same applies to the losses incurred. With revenue growth slowing down dramatically and operating leverage coming to a standstill, I am leaning cautious about Tempus here.
One of the season's most highly anticipated initial public offerings (IPOs) is taking place today. Tempus AI (NASDAQ: TEM ), a company bringing artificial intelligence (AI) to the data processing space, begins trading today after weeks of anticipation.
SoftBank Group-backed Tempus AI announced on Thursday the pricing of its initial public offering of 11.1 million ordinary shares at a price of $37 apiece.
Tempus AI stock is preparing for an initial public offering ( IPO ) and we have all of the details that traders need to know about before it gets here. Let's get into all of the latest Tempus AI IPO details below ahead of its potential listing this week!
Tempus AI Inc. is about to give investors a way to play the intersection of medicine and artificial intelligence.
Tempus AI is targeting a valuation of up to $6.10 billion in its initial public offering in the United States, the genetics testing company said on Wednesday.